Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025

Reuters

08/26

Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025

INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562735150"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562735150\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562735150?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562735150","market":"nz","top_or_hot":-1,"title":"Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-26 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INO","symbol_name":"伊诺维奥制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nNDL1hwbl:1","article_id":"2562735150","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562735150","pubTimestamp":1756209920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025. INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration  has agreed to their rolling submission plan for the Biologics License Application  for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis . The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INO":"伊诺维奥制药","BK4568":"美国抗疫概念","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"Inovio Pharmaceuticals Inc.开始滚动提交INO-3107用于RRP治疗的BLA，目标是在2025年底前获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":0.9},"content_text":"Inovio Pharmaceuticals Inc. Begins Rolling Submission of BLA for INO-3107 for RRP Treatment, Aiming for FDA Approval by End of 2025\n    \n\n        INOVIO Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has agreed to their rolling submission plan for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company is on track to complete the submission in the second half of 2025 and aims for file acceptance by the end of the year. INOVIO, which focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, is leveraging its Breakthrough Therapy designation to expedite discussions with the FDA. This development is seen as a significant step toward providing a new therapeutic option for patients suffering from RRP. There is no mention of grant or funding being obtained by multiple organizations; the announcement pertains solely to INOVIO Pharmaceuticals Inc.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH58699) on August 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}